X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2023 April 27, 2023 argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023 April 18, 2023 argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting April 17, 2023 argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology March 17, 2023 argenx Announces Annual General Meeting of Shareholders on May 2, 2023 March 15, 2023 argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis March 2, 2023 argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update March 2, 2023 argenx Announces Planned Transition of Chief Operating Officer February 27, 2023 argenx Appoints Steve Krognes to Board of Directors February 27, 2023 argenx to Present at Upcoming Investor Conferences February 24, 2023 argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023 January 27, 2023 argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod January 16, 2023 argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »